Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities Healthcare Conference

Keryx Biopharmaceuticals, Inc. to Present at the 9th Annual JMP Securities
Healthcare Conference

Presentation Scheduled for Tuesday, June 24th at 3:00 p.m. ET

NEW YORK, June 17, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX) today announced that Ron Bentsur, the Company's Chief Executive
Officer, will be presenting a corporate overview at the 9^th Annual JMP
Securities Healthcare Conference to be held at the Westin New York Grand
Central, in New York City. Mr. Bentsur's presentation will take place on
Tuesday, June 24, at 3:00 p.m. Eastern Time.

A live audio webcast of Mr. Bentsur's presentation will be accessible within
the Investor Relations section of the Company's website at
http://investors.keryx.com. An archived version of this webcast will be
available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing
innovative therapies to market for patients suffering from renal disease. In
the United States, Zerenex^TM (ferric citrate) is currently under review by
the Food and Drug Administration (FDA) for the treatment of hyperphosphatemia
in dialysis-dependent chronic kidney disease (CKD) patients. In January 2014,
ferric citrate was approved for the treatment of patients with all stages of
CKD in Japan, where it is being marketed as Riona^® by Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd.

CONTACT: Amy Sullivan
         Vice President - Corporate Development and Public Affairs
         Keryx Biopharmaceuticals, Inc.
         Tel: 617.466.3447
         E-mail: amy.sullivan@keryx.com

Keryx Logo
 
Press spacebar to pause and continue. Press esc to stop.